Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

NCT06654336 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

Prostate Adenocarcinoma
Castration Sensitive Prostate Cancer

Interventions

RADIATION: Recurrence-directed therapy (RDT)
DRUG: ELIGARD 22.5mg

Sponsor

Ontario Clinical Oncology Group (OCOG)